Structural optimization improves pharmacokinetics and functional activity of CHI3L1 inhibitors in glioblastoma, suggesting their potential for drug development.
as a CHI3L1 inhibitor with a superior pharmacokinetic profile and robust functional activity, marking it as a promising candidate for further GBM drug development.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: